In its complaint, BMS alleges that HHS' Health Resources and Services Administration (HRSA), which has responsibility for ...

Padcev, a drug Pfizer acquired in 2023, is a part of the only chemo-free treatment for bladder cancer patients newly ...

Bristol Myers Squibb Co. is challenging a federal health agency for denying its plan to implement a rebate model for its ...

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term ...

Laboratory testing for inflammation, such as the C-reactive protein test and the erythrocyte sedimentation rate, are almost ...

(Reuters) -Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established drugs like blood thinner Eliquis and cancer treatment Revlimid ...